OptimizeRx (OPRX)
(Real Time Quote from BATS)
$10.04 USD
+0.12 (1.21%)
Updated Jul 11, 2024 01:24 PM ET
2-Buy of 5 2
C Value B Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OPRX 10.04 +0.12(1.21%)
Will OPRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for OPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OPRX
Does OptimizeRx (OPRX) Have the Potential to Rally 34.78% as Wall Street Analysts Expect?
Open Text (OTEX) Q3 Earnings Meet Estimates
OPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging -22.84% in 4 Weeks, Here's Why the Trend Might Reverse for OptimizeRx (OPRX)
Down -18.75% in 4 Weeks, Here's Why You Should You Buy the Dip in OptimizeRx (OPRX)
Bruker (BRKR) Q4 Earnings and Revenues Top Estimates
Other News for OPRX
Critical Insights From OptimizeRx Analyst Ratings: What You Need To Know
Analysts’ Opinions Are Mixed on These Healthcare Stocks: OptimizeRx (OPRX) and CSL (OtherCMXHF)
New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations
OptimizeRx publishes white paper on closing the health information gap
OptimizeRx Breaks Below 200-Day Moving Average - Notable for OPRX